European Regulators Warn Of Anemia Drug Risks

Law360, New York (June 27, 2008, 12:00 AM EDT) -- Europe's drug regulating body has recommended that a class of anemia drugs often used to treat cancer patients update warning labels to say the drug could hasten the progression of cancer.

The recommendation, announced Thursday by the European Medicines Agency, applies to drugs containing the chemical epoetin. These drugs, known as erythropoiesis-stimulating agents, include Amgen Inc.'s Aranesp and Johnson & Johnson subsidiary Ortho Biotech Products LLP's Eprex, sold in the U.S. as Procrit.

ESAs are commonly used to treat anemia caused by chemotherapy and HIV medications....
To view the full article, register now.